These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1567 related items for PubMed ID: 18525320
1. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C. Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320 [Abstract] [Full Text] [Related]
2. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676 [Abstract] [Full Text] [Related]
3. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M, Ruka W. J Surg Oncol; 2006 Mar 15; 93(4):304-11. PubMed ID: 16496358 [Abstract] [Full Text] [Related]
4. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY. Chin Med J (Engl); 2010 Jan 20; 123(2):131-6. PubMed ID: 20137358 [Abstract] [Full Text] [Related]
16. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding]. Siewert E, Tietze L, Maintz C, Geier A, Dietrich CG, Matern S, Gartung C. Z Gastroenterol; 2004 Mar 20; 42(3):233-42. PubMed ID: 15022111 [Abstract] [Full Text] [Related]
17. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P. Ann Surg Oncol; 2013 Feb 20; 20(2):586-92. PubMed ID: 22965573 [Abstract] [Full Text] [Related]
18. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Cancer; 2006 Apr 01; 106(7):1617-23. PubMed ID: 16518826 [Abstract] [Full Text] [Related]
19. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Histopathology; 2005 Jul 01; 47(1):41-7. PubMed ID: 15982322 [Abstract] [Full Text] [Related]
20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Am J Surg Pathol; 2009 Feb 01; 33(2):218-26. PubMed ID: 18830121 [Abstract] [Full Text] [Related] Page: [Next] [New Search]